tirzepatide cardiovascular trial

tirzepatide cardiovascular trial vs Dulaglutide for Outcomes (SURPASS-CVOT) | NEJM Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

Name: tirzepatide cardiovascular trial vs Dulaglutide for Outcomes (SURPASS-CVOT) | NEJM Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular
Brand: inmobiliariafranchi.com
SKU: 46059069459
Price: 29.22 USD
Availability: InStock
Rating: 4.2187 (21 reviews)

SKU: 46059069459

4.2

EUR29.22 EUR63.22

Pay in 4 interest-free payments of $7.30 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 29 - Sep 3

Description

Objective diagnostics: Clear medical evidence makes claims stronger

At a maintenance dose of 1.2 to 2.3mg, pricing climbs to $399 to $499 or more a month, which can undo the upfront savings for patients who spend most of treatment at maintenance